Generic drug of the therapeutic class: Allergology
Active ingredients: Brompheniramine
Bottle (+ double spoon measures 2.5 ml / 5 ml) of 125 ml
Symptomatic treatment of various allergic manifestations:
- rhinitis (seasonal or perennial),
Dosage DIMEGAN 0.04% Syrup Bottle (+ double spoon measures 2.5 ml / 5 ml) 125 ml
The maximum daily dose of brompheniramine is 6 mg in infants and children under 6 years of age, 12 mg in children 6 to 12 years of age and 24 mg in children over 12 years of age. 'adult.
Use the double measuring spoon of 2.5 and 5 ml :
- Infant and child under 6 years: 1 to 2 scoops of 2.5 ml per dose, 3 times a day.
- Child from 6 to 12 years: 1 to 2 scoops of 5 ml per dose, 3 times a day.
- Child over 12 years and adult: 2 measuring spoons of 5 ml per dose, 3 to 4 times a day.
- The catches must be spaced at least 4 hours apart.
- It is advisable to favor the evening intake of this drug because of the sedative effect of brompheniramine.
This medicine is CONTRAINDICATED in the following situations:
hypersensitivity to the constituents of the product and in particular to antihistamines and parabens,
- risk of urinary retention related to urethroprostatic disorders,
- risk of glaucoma by closing the angle.
NOT RECOMMENDED :
- THIS MEDICATION SHOULD NOT GENERALLY BE USED DURING THE FIRST QUARTER OF Pregnancy and Breastfeeding:
. Pregnancy: There is no reliable animal teratogenicity data for brompheniramine . In the clinic, the few cases of exposed pregnancies seem to evoke a malformative effect of brompheniramine . Additional studies are needed to confirm this risk, which can not be ruled out to date. Given these data, the use of this drug is not recommended during the first trimester of pregnancy,
. breastfeeding: Brompheniramine passes into breast milk. Due to the sedative properties of brompheniramine, this medication is not recommended during breastfeeding.
- Taking alcoholic beverages and drugs containing alcohol (see chapter interactions) during treatment is strongly discouraged.
Dimegan side effects
The pharmacological characteristics of brompheniramine lead to adverse effects of unequal intensity and dose-related or non-dose-related (see pharmacodynamic properties):
- Neurovegetative effects:
. sedation or drowsiness, more marked at the beginning of treatment,
. anticholinergic effects such as dryness of the mucous membranes, constipation, accommodation disorders, mydriasis, heart palpitations, risk of urinary retention,
. orthostatic hypotension,
. balance disorders, dizziness, decreased memory or concentration (more common in the elderly),
. motor incoordination, tremors,
. mental confusion, hallucinations;
- Hematological effects:
. leukopenia, neutropenia,
. hemolytic anemia;
- Awareness Reactions:
. erythema, eczema, pruritus, purpura, possibly giant urticaria,
. edema, more rarely angioedema,
. anaphylactic shock.